Kent and Canterbury Hospital
Kent and Canterbury Hospital
Canterbury, United Kingdom4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Recruiting | Phase 3 | 2026-03-24 | NCT03994471 | |
| Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, cancer, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder, rectal disorder, skin disorder | Active, not recruiting | Phase 3 | 2025-06-10 | NCT02804815 | |
| Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) | Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer | Active, not recruiting | Phase 3 | 2025-02-19 | NCT02215265 | |
| Prostate Advances in Comparative Evidence | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2024-01-19 | NCT01584258 |